Search results
Results from the WOW.Com Content Network
Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. [1] Dopamine receptors are therefore common drug targets. Dopamine receptors activate different effectors through not only G-protein coupling, but also signaling through different protein (dopamine receptor-interacting ...
Other dopaminergic drugs that have been used or suggested in the treatment of disorders of diminished motivation include rasagiline (a selective monoamine oxidase B (MAO-B) inhibitor; but see more below), tolcapone (a centrally-acting catechol-O-methyltransferase (COMT) inhibitor), and amantadine (an indirectly acting dopaminergic agent that ...
These agents stimulate dopamine receptors. In doing so, they alleviate the symptoms associated with Parkinson's disease . Wikimedia Commons has media related to Dopamine agonists .
In Parkinson's disease dopaminergic neurons that produce the neurotransmitter dopamine in the brain slowly break down and can eventually die. With decreasing levels of dopamine the brain can't function properly and causes abnormal brain activity, which ultimately leads to the symptoms of Parkinson's disease.
This results in increased extracellular concentrations of dopamine and increase in dopaminergic neurotransmission. [ 1 ] DRIs are used in the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy for their psychostimulant effects, and in the treatment of obesity and binge eating disorder for their appetite suppressant effects.
Amantadine has dopaminergic effects through uncertain mechanisms of action. [24] [25] It is structurally related to other adamantanes like bromantane and rimantadine, which also have dopaminergic actions. [26] Bromantane can upregulate tyrosine hydroxylase (TH) and thereby increase dopamine production and this might be involved in its ...
Oxidopamine (6-hydroxydopamine), a selective dopaminergic and noradrenergic neurotoxin.. A monoamine neurotoxin, or monoaminergic neurotoxin, is a drug that selectively damages or destroys monoaminergic neurons. [1]
This in turn leads to increased extracellular concentrations of both norepinephrine and dopamine and, therefore, an increase in adrenergic and dopaminergic neurotransmission. [1] A closely related type of drug is a norepinephrine–dopamine releasing agent (NDRA).